Global IVF (in-vitro fertilization) Market Overview, 2024-29

Global IVF (in-vitro fertilization) Market Overview, 2024-29

The global in vitro fertilisation (IVF) market is expanding significantly due to a number of causes, such as improved fertility treatments, raised awareness of infertility, and higher IVF procedure success rates. A variety of strategic initiatives, including collaborations, mergers and acquisitions, the opening of new fertility clinics, and the introduction of cutting-edge IVF technology, define the market. Major businesses including thermo Fisher Scientific, Vitrolife AB, Fujifilm Holdings, Merck KGaA, and Cooper Surgical Inc. are dominating the sector in what is still a very competitive and concentrated market. To meet the increasing demand for fertility treatments, these businesses are constantly improving the products they offer and enlarging where they are located. In addition to its high success rate for IVF and its supportive government policies for fertility treatments, Europe has a leading position in the region. Although the high cost of IVF treatments has led to medical tourism, when individuals travel overseas in search of more cheaper treatments, North America, also have tremendous market potential. With growing awareness, rising infertility rates, and improvements in medical tourism infrastructure, the Asia-Pacific area is predicted to develop at the fastest rate. All things considered, it is anticipated that the worldwide IVF industry will keep expanding due to advancements in technology, heightened capital allocation to fertility centres, and growing public acceptance of assisted reproductive technologies. Success rates in IVF have increased dramatically thanks to ongoing technological advancements like AI-based embryo screening and time-lapse imaging systems. For example, more accurate and customized IVF care is provided by AI technologies created by businesses like Genea Biomedx and AIVF. Couples seeking fertility treatments are becoming more common as a result of increased knowledge about infertility and its therapies as well as societal acceptance of IVF. Reducing the stigma around infertility has also been greatly aided by education and awareness programmes. Couples seeking fertility treatments are becoming more common as a result of increased knowledge about infertility and its therapies as well as societal acceptance of IVF. Reducing the stigma around infertility has also been greatly aided by education and awareness programmes.

According to the research report, “Global IVF Market Overview, 2029” published by Bonafide Research, the market is anticipated to cross USD 12 Billion by 2029, increasing from USD 39 Billion in 2023. The convergence of growing demand for fertility treatments, technological improvements, and favourable regulatory frameworks is propelling the strong expansion of the global IVF market. Leading the way in the expansion of the IVF market is technological innovation. To enhance the results of IVF, cutting-edge technology like artificial intelligence and machine learning are being incorporated. AI is especially revolutionary in the area of embryo selection; it improves the precision of selecting the healthiest embryos for implantation. Higher success rates and fewer cycles needed for each pregnancy are the effects of this. Furthermore, early detection of genetic problems is made possible by genetic screening technologies like preimplantation genetic testing (PGT), which lowers the risk of inherited diseases and increases the chance of a healthy pregnancy. Worldwide demand for IVF is increasing as a result of many societal developments. The growing number of couples choosing to put off having children for personal and professional reasons is one notable trend. Due to decreased fertility brought on by this delay, more couples are turning to IVF procedures. Furthermore, the stigma associated with infertility treatments is fading as more people become aware of and accept IVF and other assisted reproductive technologies (ART). This change has been largely attributed to awareness-raising and educational initiatives that have encouraged more people to choose IVF. The growing number of fertility clinics, especially in developing nations, is increasing the accessibility of IVF procedures. For instance, the number of fertility clinics is expanding quickly in the Asia-Pacific area as a result of better healthcare facilities and increasing awareness of infertility. A significant additional component propelling industry expansion is medical tourism. Due to the high expense of IVF treatments in affluent nations like the US, many patients are looking for more reasonable treatment options overseas. Numerous overseas patients are drawn to nations like Thailand, Mexico, and India because they provide excellent IVF care at reasonable prices.

Market Drivers

• Delayed Parenthood: A trend towards delayed parenthood due to career aspirations and personal reasons has led to an increased demand for fertility treatments as fertility naturally declines with age.
• Growing Awareness and Acceptance: Greater awareness about infertility and available treatments, along with decreasing societal stigma around assisted reproductive technologies, is encouraging more couples to seek IVF treatments.

Market Challenges

• Ethical and Legal Issues: IVF treatments involve various ethical and legal challenges that vary significantly across different countries. Issues such as the use of donor gametes, surrogacy, and the ethical implications of embryo selection can create complex legal landscapes.
• Variable Success Rates: The success rates of IVF treatments are not guaranteed and can vary widely based on factors such as age, underlying fertility issues, and the specific protocols used by clinics. While technological advancements have improved success rates, they still remain around 30-40% per cycle for women under 35, with decreasing rates for older women.

Market Trends

• Fertility Preservation: there is a growing trend toward fertility preservation, especially among younger individuals who choose to delay parenthood due to career or personal reasons. Techniques such as egg and sperm freezing (cryopreservation) allow individuals to preserve their gametes for future use.
• Personalized Medicine: Personalized medicine is becoming increasingly important in IVF treatments. Tailoring IVF protocols to the specific needs and genetic profiles of patients can improve success rates and reduce the number of cycles required to achieve pregnancy. Advances in genetic testing and personalized treatment plans are making IVF more effective and patient-centric.

Segmentation by cycle enables the identification of trends over time, including changes in patient preferences, advancements in technology, and shifts in clinical outcomes.

Understanding the in vitro fertilisation (IVF) market dynamics, especially with regard to fresh non-donor cycles, requires a segmentation analysis per cycle. For many couples seeking fertility therapy, these cycles are their main choice and account for a sizable percentage of IVF treatments. In a fresh non-donor IVF cycle, the eggs are usually taken from the female spouse, sperm fertilisation occurs in a lab, and the resultant embryos are then transferred back into the uterus. This cycle differs from others in that it depends on the intended parents' biological materials, unlike donor cycles or frozen embryo transfers. Researchers and practitioners in the IVF market can evaluate a range of characteristics that impact success rates, including patient demographics, treatment procedures, and clinic practices, by examining recently completed non-donor cycles. For healthcare professionals, legislators, and industry stakeholders alike, segmentation analysis is crucial to comprehending the subtleties of new non-donor IVF cycles. It makes it easier to make well-informed decisions about treatment plans, how to allocate resources, and how to create plans to enhance patient outcomes and access to care in the ever-changing field of assisted reproductive technologies.

IVF with ICSI has gained prominence, particularly in cases of male factor infertility or previous failed fertilization attempts with conventional IVF.

Assessing the dynamics of the IVF industry, especially with regard to assisted reproductive technologies, can be gained by segmenting the market by conventional IVF and IVF with Intracytoplasmic Sperm Injection (ICSI). Eggs and sperm are fertilized in a culture dish during conventional IVF, allowing natural selection to choose which sperm fertilizes the egg. It is not necessary for sperm to pass through the egg's outer layer when doing IVF with ICSI, as a single sperm is directly injected into the egg. Researchers and practitioners can gain insights into the frequency and trends of individual methods in the IVF market by examining segmentation based on these procedures. For many years, conventional in vitro fertilisation (IVF) has been the mainstay of assisted reproduction, providing many infertile couples with an affordable and efficient treatment option. Stakeholders can evaluate variables related to each approach, including success rates, patient demographics, and clinical outcomes, by using segmentation analysis by conventional IVF and IVF with ICSI. It also aids in identifying new trends, developments in technology, and areas in the IVF industry that require more study and development. Healthcare professionals, legislators, and industry stakeholders must comprehend the subtle differences between IVF with ICSI and conventional IVF through segmentation analysis. In the rapidly changing field of assisted reproductive technology, it facilitates well-informed decision-making about the choice of treatment, the distribution of available resources, and the creation of plans to improve patient outcomes and access to care.

it helps identify areas for collaboration and partnership between hospitals, surgical centers, and other stakeholders involved in the provision of IVF services.

The in vitro fertilisation (IVF) market's dynamics can be better understood by doing segmentation analysis by end-user, with a particular focus on hospitals and surgical centres. IVF treatments are primarily provided by hospitals and surgical centres, which provide patients pursuing fertility therapy with specialised equipment, knowledgeable staff, and all-encompassing care. Scholars and practitioners can gain insight into the distribution of IVF services in various healthcare settings by examining end-user segmentation in the IVF market. The patient base served by hospitals and surgical centres is varied, encompassing both persons in need of advanced reproductive procedures like IVF and those seeking simple fertility evaluations. Optimizing resource allocation, improving service delivery, and raising patient satisfaction all depend on an understanding of the patient's preferences and patterns of use in these contexts. It enables stakeholders to assess factors such as treatment volumes, clinical outcomes, and patient experiences across different healthcare settings. Additionally, it helps identify areas for collaboration and partnership between hospitals, surgical centers, and other stakeholders involved in the provision of IVF services. Understanding the role of hospitals and surgical centers through segmentation analysis is crucial for healthcare providers, policymakers, and industry stakeholders. It supports informed decision-making regarding service planning, investment priorities, and the development of strategies to enhance access to high-quality IVF care for patients worldwide.

Different regions exhibit distinct patterns influenced by factors such as population demographics, socioeconomic conditions, cultural attitudes towards fertility treatment, and healthcare infrastructure.

Whether it comes to understanding geographic differences in demand, adoption rates, regulatory environments, and market dynamics, regional analysis is crucial in the in vitro fertilisation (IVF) industry. There is typically more access to and knowledge of IVF services in industrialized nations like North America and Europe. Increased adoption rates of IVF procedures are partly attributed to these areas' strong regulatory frameworks, well-established healthcare systems, and higher disposable incomes. Cultural influences may also be important, as evidenced by the increasingly progressive views on family planning and reproductive technology. The IVF industry, however, may expand quickly in emerging nations in Asia, Latin America, and the Middle East due to things like increased rates of infertility, rising disposable incomes, and bettering healthcare infrastructure. In addition to the accessibility and price of IVF services, cultural, religious, and societal norms around fertility therapy may also have an impact on adoption rates in these areas. Stakeholders can detect market opportunities, customise marketing plans, and deal with particular issues in each region by using regional analysis. It helps businesses to negotiate regulatory restrictions in many countries and modify their goods and services to suit the needs of various patient populations.

• In June 2023, The debut of MilliporeSigma's new CellToxTM Assay Platform was announced. The platform consists of a collection of in vitro tests intended to evaluate the safety of substances and medications.
• In May 2023, WuXi AppTec announced that its in vitro toxicological capabilities have expanded. New assays will be included as part of the expansion and a new service for creating personalized in vitro assays will be introduced.
• In April 2023, Thermo Fisher Scientific Inc. said that it had acquired CooperSurgical, an IVF supplier of goods and services. Thermo Fisher will be able to increase its market share in the IVF sector thanks to the acquisition.

Considered in this report
• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029

Aspects covered in this report
• IVF market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By cycle
• Fresh Non-donor IVF Cycle
• Frozen Non-donor IVF Cycle
• Frozen donor IVF Cycle
• Fresh donor IVF Cycle

By Conventional IVF
• Conventional IVF
• IVF with ICSI (Instracytoplasmic Sperm Injection)
• IVF With Donor Eggs
• other

By End user
• Fertility Clinics
• Hospital & Surgical Centers
• Cryobanks
• Research institute

The approach of the report:
This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the IVF industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.
***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.